News & Updates

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

Mepolizumab does not appear to reduce the symptoms of dysphagia as compared with placebo in the treatment of individuals with eosinophilic oesophagitis (EoE), although the drug helps reduce eosinophil counts and endoscopic severity, according to a study.

Mepolizumab does little to improve dysphagia symptoms

17 Jul 2023

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023 by

In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

11 Jul 2023

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

10 Jul 2023

A phenome-wide association study (pheWAS) has found known and potentially new risk factors for gastrointestinal (GI) dysfunction in systemic sclerosis (SSc), which include drug classes such as opioid, antimuscarinic, and endothelin receptor antagonist, and antinuclear antibodies (ANAs) subgroup.

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

10 Jul 2023

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023 by

The ileal bile acid transporter (IBAT) inhibitor maralixibat appears to quell itching and reduce serum bile acid concentration in children with progressive familial intrahepatic cholestasis (PFIC), while having a tolerable safety profile, according to data from the phase III MARCH-PFIC trial said to be the largest to date.

Another IBAT inhibitor makes its case in large PFIC trial

30 Jun 2023

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023 by

In a pooled analysis of two long-term paediatric extension trials evaluating short bowel syndrome-associated intestinal failure (SBS-IF), the glucagon-like peptide-2 analogue teduglutide (TED) demonstrated a safety profile that aligned with previous data.

Long-term data support teduglutide safety for SBS-IF

30 Jun 2023

$Faecal transplant helps teens with refractory IBS$

Faecal transplant helps teens with refractory IBS

29 Jun 2023 by

For adolescents with treatment-refractory irritable bowel syndrome (IBS), faecal microbiota transplantation (FMT) is safe and beneficial, easing abdominal pain and improving health-related quality of life, according to a study presented at ESPGHAN 2023.

Faecal transplant helps teens with refractory IBS

29 Jun 2023

PPI use ups mortality risk in ICU patients

29 Jun 2023

Use of proton pump inhibitors (PPIs) for the prevention of stress ulceration appears to elevate the risk of mortality in patients admitted to the intensive care unit (ICU), reveals a study.

PPI use ups mortality risk in ICU patients

29 Jun 2023

Gas-filled on par with fluid-filled IGB for obesity treatment

28 Jun 2023

Current Food and Drug Administration (FDA)-approved intragastric balloon (IGB) systems, the gas-filled IGB (Obalon) and the fluid-filled IGB (Orbera), demonstrate similar effectiveness for the treatment of obesity, as shown in a recent study.

Gas-filled on par with fluid-filled IGB for obesity treatment

28 Jun 2023

Peroral endoscopic myotomy offers long-term benefits in jackhammer esophagus

27 Jun 2023

Treatment with peroral endoscopic myotomy (POEM) demonstrates long-term efficacy in patients with jackhammer esophagus (JE), a rare hypercontractile motility disorder often associated with dysphagia, regurgitation, and chest pain, reports a study.

Peroral endoscopic myotomy offers long-term benefits in jackhammer esophagus

27 Jun 2023

New scorecard helps detect peanut allergy

27 Jun 2023 by

Paediatricians may have a new tool in a scorecard that could ably detect peanut allergy in infants with atopic dermatitis (AD).

New scorecard helps detect peanut allergy

27 Jun 2023

News & Updates

Filter by Specialty:

Specialty:

Mepolizumab does little to improve dysphagia symptoms

Mepolizumab does little to improve dysphagia symptoms

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

‘Triple-G’ obesity drug also targets NAFLD in phase II trial

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

Certain drugs, antinuclear antibodies linked to GI dysfunction in SSc

Another IBAT inhibitor makes its case in large PFIC trial

Another IBAT inhibitor makes its case in large PFIC trial

Long-term data support teduglutide safety for SBS-IF

Long-term data support teduglutide safety for SBS-IF

Faecal transplant helps teens with refractory IBS

Faecal transplant helps teens with refractory IBS

PPI use ups mortality risk in ICU patients

PPI use ups mortality risk in ICU patients

Gas-filled on par with fluid-filled IGB for obesity treatment

Gas-filled on par with fluid-filled IGB for obesity treatment

Peroral endoscopic myotomy offers long-term benefits in jackhammer esophagus

Peroral endoscopic myotomy offers long-term benefits in jackhammer esophagus

New scorecard helps detect peanut allergy

New scorecard helps detect peanut allergy